NUVB News and Press, Nuvation Bio Inc. Class A From 01/08/24

2024-01-08 16:39:14 ET More on Nuvation Bio Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio For further details see: FDA clears Nuvation to begin Phase 1/2 study for onco...

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors. “We are delighted to have D...

NUV-1511 is the first clinical candidate from the company’s novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet ...

2023-11-28 23:26:48 ET Summary Abrams' 13F portfolio value decreased from $3.48B to $3.03B this quarter, with the number of holdings decreasing from 16 to 14. The top three stakes make up approximately 49% of the portfolio, while the top five holdings account for around 67%. T...

2023-11-13 16:23:02 ET More on Nuvation Bio Nuvation: Cash Is King, Science Is An Afterthought Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio For further details see...

Nuvation Bio Inc. (NYSE: NUVB) (the “Company”) announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. Ms. Fox has advised the Company that she is seeking later stage development and commercial launch experience a...

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash equivalents, and marketa...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Nuvation Bio Inc. Class A (NUVB) is expected to report $-0.1 for Q3 2023

2023-10-03 04:47:57 ET Summary Nuvation Bio is developing BET inhibitors for solid tumors, with lead asset NUV-868 in phase 1/1b trials. BET proteins play a role in gene regulation and chromatin remodeling, and inhibiting them may be therapeutic for cancer. NUV-868 is highly s...